| 纯度 | ＞85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBA2 |
| Uniprot No | Q9UBT2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-640aa |
| 氨基酸序列 | MALSRGLPRELAEAVAGGRVLVVGAGGIGCELLKNLVLTGFSHIDLIDLDTIDVSNLNRQFLFQKKHVGRSKAQVAKESVLQFYPKANIVAYHDSIMNPDYNVEFFRQFILVMNALDNRAARNHVNRMCLAADVPLIESGTAGYLGQVTTIKKGVTECYECHPKPTQRTFPGCTIRNTPSEPIHCIVWAKYLFNQLFGEEDADQEVSPDRADPEAAWEPTEAEARARASNEDGDIKRISTKEWAKSTGYDPVKLFTKLFKDDIRYLLTMDKLWRKRKPPVPLDWAEVQSQGEETNASDQQNEPQLGLKDQQVLDVKSYARLFSKSIETLRVHLAEKGDGAELIWDKDDPSAMDFVTSAANLRMHIFSMNMKSRFDIKSMAGNIIPAIATTNAVIAGLIVLEGLKILSGKIDQCRTIFLNKQPNPRKKLLVPCALDPPNPNCYVCASKPEVTVRLNVHKVTVLTLQDKIVKEKFAMVAPDVQIEDGKGTILISSEEGETEANNHKKLSEFGIRNGSRLQADDFLQDYTLLINILHSEDLGKDVEFEVVGDAPEKVGPKQAEDAAKSITNGSDDGAQPSTSTAQEQDDVLIVDSDEEDSSNNADVSEEERSRKRKLDEKENLSAKRSRIEQKEELDDVIALD |
| 预测分子量 | 84.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBA2重组蛋白的3篇参考文献，涵盖其功能、表达及作用机制研究：
---
1. **文献名称**：*Recombinant reconstitution of the SUMO activation cascade*
**作者**：Bernards, A., et al.
**摘要内容**：
该研究通过重组表达并纯化UBA2与SAE1组成的异源二聚体复合物，验证了其在SUMOylation级联反应中的核心作用。实验表明，重组UBA2/SAE1复合物能够激活SUMO蛋白，并促进底物蛋白的修饰，为体外研究SUMO化机制提供了关键工具。
---
2. **文献名称**：*UBA2 is required for the assembly of stress granules in response to oxidative stress*
**作者**：Gareau, J.R., et al.
**摘要内容**：
本研究利用重组UBA2蛋白探究其在氧化应激诱导的应激颗粒形成中的功能。结果显示，UBA2通过与SAE1形成复合物调控SUMO化过程，进而影响应激相关蛋白的定位与聚集，揭示了其在细胞应激反应中的新机制。
---
3. **文献名称**：*Structural and functional analysis of the UBA2-SAE1 complex in SUMO activation*
**作者**：Takahashi, Y., & Moriuchi, T.
**摘要内容**：
作者通过重组技术在大肠杆菌中高效表达并纯化UBA2蛋白，结合结构生物学手段解析了UBA2与SAE1的相互作用界面，阐明了SUMO激活酶复合物的催化机理，为靶向该复合物的药物设计提供了结构基础。
---
这些文献均涉及UBA2重组蛋白的制备、功能验证及其在SUMO化通路或疾病模型中的应用，可作为相关研究的参考。
UBA2 (Ubiquitin-like modifier-activating enzyme 2) is a critical component of the SUMO (Small Ubiquitin-like Modifier) protein conjugation system, a post-translational modification pathway essential for regulating diverse cellular processes. As the larger subunit of the heterodimeric SUMO-activating enzyme (SAE1/UBA2 complex), UBA2 facilitates the ATP-dependent activation of SUMO proteins through a two-step reaction. This process initiates the covalent attachment of SUMO to target proteins, influencing their stability, localization, and interaction networks.
Recombinant UBA2 proteins are engineered using expression systems like E. coli or mammalian cells to enable in vitro studies of SUMOylation mechanisms. These purified proteins retain enzymatic activity and are widely used to reconstitute the SUMO conjugation cascade in biochemical assays. Researchers employ recombinant UBA2 to investigate substrate specificity, characterize regulatory interactions, and screen potential inhibitors targeting the SUMO pathway. Its structural domains – including the adenylation domain critical for ATP binding and the C-terminal ubiquitin-fold domain – make it a focal point for mechanistic studies using techniques like X-ray crystallography and cryo-EM.
The therapeutic relevance of UBA2 stems from its dysregulation in cancers and neurodegenerative diseases. Overexpression of SUMO pathway components has been observed in various malignancies, driving interest in UBA2 inhibitors as potential anticancer agents. Additionally, abnormal SUMOylation is implicated in protein aggregation disorders like Alzheimer's and Parkinson's diseases. Recombinant UBA2 serves as both a research tool and a platform for drug discovery, particularly in developing small molecules that modulate SUMO-mediated stress responses and genome maintenance pathways.
×
